Download Free Bone Drugs In Pediatrics Book in PDF and EPUB Free Download. You can read online Bone Drugs In Pediatrics and write the review.

There has been a rapid expansion of knowledge in the field of paediatric calcium and bone disorders over the past twenty years. Advances have been made in the underlying genetic basis for many conditions in conjunction with progress in bone density and geometry imaging and the development of new treatment options. The 2nd revised edition of ‘Calcium and Bone Disorders in Children and Adolescents’ presents up-to-date information on many aspects included in the 1st edition such as the physiology, pathology, diagnosis and management of numerous conditions including a chapter of case histories illustrating clinical aspects. New chapters on skeletal dysplasias, the genetics of osteoporosis, radiological imaging of bone and a practical approach to a child with recurrent fractures are included. Providing a comprehensive update, this book is a useful clinical resource for paediatricians and specialists in endocrinology, metabolic bone disease, nephrology, rheumatology, radiology, orthopaedics and clinical genetics who may be faced with a child with a calcium and/or bone disorder.
Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves – such as bisphosphonates, antiresorptives and anabolic agents – within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs in future treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.
Pediatric osteology, a medical specialty that has come of age, has contributed to the understanding of adult bone diseases as well. This second edition reference updates the 2003 edition with more emphasis on management as well as new and revised contributions. Thirty chapters present basic information regarding bone development, tools and techniques for evaluation (including a new chapter on radiographic imaging), and the specifics of various diseases. The three editors are affiliated as follows: Francis H. Glorieux (McGill U., Canada), John M. Pettifor (Chir Hani Baragwanath Hospital, South Africa), and Harald Juppner (Harvard Medical School, US). Academic Press is an imprint of Elsevier. Annotation ©2012 Book News, Inc., Portland, OR (booknews.com).
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
The field of pediatric bone and soft tissue sarcomas has experienced a gradual but surprising transformation. Fundamental discoveries in the molecular biology of disease, recent breakthroughs in diagnostic imaging, and revolutionary surgical techniques have created unprecedented synergies and a refreshing vision with which to approach the diagnosis and treatment of these pediatric tumors. This book highlights the paths leading to the emergence of such a new vision and presents salient concepts in epidemiology, novel tools in imaging and molecular biology, and principles of drug development as the scaffold to understanding the pathophysiology and treatment of pediatric sarcomas. The book is aimed at providing an up-to-date comprehensive reference text which articulates a multidisciplinary approach for the diagnosis and treatment of each of these often challenging diseases.
Osteoporosis, a growing epidemic among women in North America, Europe, and Japan, is a painful, costly disease that has presented a treatment challenge to healthcare professionals. Until recently, therapies have focused on agents that slow bone resorption, and have had only limited success at increasing bone mass. However, exciting new developments are on the verge of changing the treatment of this debilitating disorder. Two anabolic agents, the parathyroid hormone (PTH) and the fluoride ion, show tremendous promise as tools for building and retaining bone - with no adverse side effects. Anabolic Treatments for Osteoporosis is a comprehensive account of the latest studies that have been carried out on these two agents, and a thorough assessment of their prospects as osteoporosis therapeutics. This unique book combines basic science and up-to-date clinical data to present a complete picture of this breakthrough in the treatment of a globally significant health issue.
This book provides a review of the most recent data on osteoporosis and bone health, presenting a vision of diagnosis and management for the year 2021 and beyond. It covers all pertinent aspects of bone health including diagnosis, fracture prevention, optimized practice, impaired orthostasis, and falls. The book examines recent developments in therapeutics, including goal-directed therapy, individualizing therapy, sequential and combined therapies, pharmaceuticals, and anabolic vs. antiresorptive therapy. In addition, it provides an in-depth overview of osteoporosis and bone health in complex patients, covering Duchene dystrophy, renal failure, periodontal diseases, and steroid-induced osteoporosis as well as considerations for pediatric populations and men. New Horizons in Osteoporosis Management is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses in rheumatology, endocrinology, radiology, pediatrics, primary care, and internal medicine.
This first-ever Surgeon General's Report on bone health and osteoporosis illustrates the large burden that bone disease places on our Nation and its citizens. Like other chronic diseases that disproportionately affect the elderly, the prevalence of bone disease and fractures is projected to increase markedly as the population ages. If these predictions come true, bone disease and fractures will have a tremendous negative impact on the future well-being of Americans. But as this report makes clear, they need not come true: by working together we can change the picture of aging in America. Osteoporosis, fractures, and other chronic diseases no longer should be thought of as an inevitable part of growing old. By focusing on prevention and lifestyle changes, including physical activity and nutrition, as well as early diagnosis and appropriate treatment, Americans can avoid much of the damaging impact of bone disease and other chronic diseases. This Surgeon General's Report brings together for the first time the scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. More importantly, it provides a framework for moving forward. The report will be another effective tool in educating Americans about how they can promote bone health throughout their lives. This first-ever Surgeon General's Report on bone health and osteoporosis provides much needed information on bone health, an often overlooked aspect of physical health. This report follows in the tradition of previous Surgeon Generals' reports by identifying the relevant scientific data, rigorously evaluating and summarizing the evidence, and determining conclusions.
Osteoporosis is one of the most clinically relevant disabling chronic disease encountered in clinical practice. A common cause of osteoporosis is glucocorticoid excess, as glucocorticoids may increase bone resorption, inhibit bone formation, have indirect actions on bone by decreasing intestinal calcium absorption and induce hypercalciuria. This book presents a comprehensive overview of the effects of glucocorticoids on bone metabolism and structure and on the diagnosis and treatment of glucocorticoid-induced osteoporosis. It aims at providing updated information on the pathogenesis, diagnosis and treatment of this often dramatic complication of glucocorticoid excess. Being one of the few publications completely devoted to glucocorticoid-induced osteoporosis it will heighten the awareness of specialists who prescribe glucocorticoids of the clinical relevance of this treatment complication. 'Glucocorticoid-Induced Osteoporosis' is addressed to clinical experts as well as to general practitioners who will both benefit from the comprehensive and integrative view of the management of patients exposed to glucocorticoids.